Skip to main content

Steven Selde

Director
Biosimilars Council, a Division of the Association for Accessible Medicines Pharmaceutical Manufacturing
Washington, DC

Authored Items

HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use
By Steven Selde
May 2022, Vol 12, No 5
Biosimilars
Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many pharmacy benefit managers and health plans have been slow to prioritize biosimilars, leaving savings on the table. Read More ›